

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q96699

Takayoshi KAWAGUCHI, et al.

Appln. No.: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: August 31, 2006

Examiner: Not Yet Assigned

For: COMPOSITION FOR MEDICAL USE HAVING IMPROVED WATER-SOLUBILITY  
OF PEPTIDE AND METAL-LABELING EFFICIENCY AND PREPARATION FOR  
MEDICAL USE COMPRISING METAL-LABELED PEPTIDE

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby  
notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached  
PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem  
material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following:  
U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications  
filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three  
months from the application's filing date; (2) Before the mailing date of the first Office Action

INFORMATION DISCLOSURE STATEMENT  
U.S. Appln. No. Not Yet Assigned

on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Peter D. Olexy  
Registration No. 24,513

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
23373  
CUSTOMER NUMBER

Date: August 31, 2006

**Substitute for Form 1449 A & B/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet

1

of

**Attorney Docket Number**

10/591252

Application Number	Not Yet Assigned
Confirmation Number	Not Yet Assigned
Filing Date	August 30, 2006
First Named Inventor	Takayoshi KAWAGUCHI
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q96699

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		BEHR, T.M. et al., Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives, <i>Cancer research</i> , 1995, Vol. 55, No. 17, p. 3825-34	English
		VERBEKE, K. et al., Influence of the bifunctional chelate on the biological behavior of (99m)Tc-labeled chemotactic peptide conjugates, <i>Nucl. Med. Biol.</i> , 2000, Vol. 27, No. 8, p.769-79	English
		VAN DER LAKEN, C. J. et al., Technetium-99m-labeled Chemotactic Peptides in acute infection and sterile inflammation; <i>The Journal of Nuclear Medicine</i> , Vol. 38, No. 8, August 1997, p. 1310-1315	English

**Examiner Signature** \_\_\_\_\_ **Date Considered** \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.